Rallybio Corp (RLYB NASDAQ) stock market data APIs
$0.335
-0.01(-3%)
as of June 30, 2025
Try our APIs with
free plan!
Rallybio Corp Financial Data Overview
Price chart is built with
Anychart
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Prev. Close
0.335
Open
0.3233
High
0.3395
Low
0.3233
52 wk Range
0.2201-1.54
Market Cap
14 066 K
Shares Outstanding
41 614 K
Revenue
848 K
EPS
-0.21
Beta
-1.239
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rallybio Corp data using free add-ons & libraries
Get Rallybio Corp Fundamental Data
Rallybio Corp Fundamental data includes:
- Net Revenue: 848 K
- EBITDA: -50 255 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.285
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rallybio Corp News
New
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatmen...
EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million. Non-operating income totaled $0.3 million, an...
2 ‘Strong Buy’ Stocks J.P. Morgan Predicts Will Surge Over 50%
The doom and gloom brigade has been out in full force recently, persistently warning the economy is in a precarious state and that a recession next year is all but inevitable. Maybe so, but that does...
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
VANCOUVER, British Columbia & NEW HAVEN, Conn., December 01, 2022--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
